文献速递青光眼

高多基因风险与早期原发性开角型青光眼中更早启动和升级治疗相关

High Polygenic Risk Is Associated with Earlier Initiation and Escalation of Treatment in Early Primary Open-Angle Glaucoma.
PubMed 文献 · Ophthalmology · 2023-04-10

这项前瞻性观察性队列研究纳入1107名参与者,计算每等位基因加权的青光眼多基因风险评分(PRS),评估PRS与启动或升级降眼压治疗的关系。结果显示较高的PRS与5年内启动降眼压治疗风险增加相关(每1个标准差HR 1.45),最高五分位组5年内启动治疗风险是最低五分位组的3.3倍;在入组时已接受治疗的患者中,较高PRS也与治疗升级风险增加相关(每1个标准差HR 1.19)。

要点

  • 较高青光眼PRS与疑似青光眼患者5年内启动降眼压治疗风险增加相关(每1个标准差HR 1.45)。
  • PRS最高五分位组5年内启动治疗风险是最低五分位组的3.3倍,2年内为5.45倍。
  • 在入组时已接受治疗者中,较高PRS与治疗升级风险增加相关(每1个标准差HR 1.19)。

核心结论

  • 本研究显示青光眼多基因风险与启动或升级降眼压治疗的风险存在新关联,建立在既往强调遗传风险分层在青光眼中潜在临床价值的工作基础上。

研究设计与样本

  • 前瞻性观察性队列研究,参与者来自青光眼进展风险:相关SNP与显著关联研究,共1107名参与者计算每等位基因加权青光眼PRS。
  • 416名入组时未治疗的疑似青光眼患者纳入PRS与启动降眼压治疗时间关联的主要分析。
  • 691名入组时正在接受降眼压治疗的疑似和早期原发性开角型青光眼患者纳入PRS与治疗升级关联的次要分析。

主要发现

  • 较高的PRS与5年内启动降眼压治疗风险增加相关(每1个标准差HR 1.45;95%CI 1.27-1.62;P < 0.001)。
  • PRS最高五分位组2年内启动降眼压治疗风险是最低五分位组的5.45倍(HR 5.45;95%CI 2.08-14.25;P < 0.001)。
  • 在入组时已接受治疗的患者中,较高PRS与治疗升级风险增加相关(每1个标准差HR 1.19;95%CI 1.09-1.31;P < 0.001)。
  • 在全部参与者的合并分析中,PRS最高五分位组需要启动或升级降眼压治疗的风险是最低五分位组的2.33倍(HR 2.33;95%CI 1.75-3.01;P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the association between a glaucoma polygenic risk score (PRS) and treatment outcomes in primary open-angle glaucoma. DESIGN: Prospective, observational cohort study. PARTICIPANTS: Participants from the Progression Risk of Glaucoma: Relevant SNPs with Significant Association Study were divided into a cohort with suspect glaucoma who were treatment naive at enrollment and one with early manifest and suspect glaucoma receiving treatment at enrollment. METHODS: A per-allele weighted glaucoma PRS was calculated for 1107 participants. Multivariable mixed-effects Cox proportional regression analysis assessed the association between PRS and time to commencement of intraocular pressure (IOP)-lowering therapy in 416 patients with suspect glaucoma who were treatment naive at study enrollment. Secondary analysis evaluated the association between PRS and escalation of IOP-lowering therapy among 691 patients with suspect and early manifest glaucoma who were receiving IOP-lowering therapy at enrollment. MAIN OUTCOME MEASURES: Commencement or escalation of IOP-lowering therapy. RESULTS: A higher PRS was associated with a greater risk of commencing IOP-lowering therapy within 5 years (hazard ratio [HR], 1.45 per 1 standard deviation [/SD]; 95% confidence interval [CI], 1.27-1.62; P < 0.001). Participants in the upper population-based quintile showed a 3.3 times greater risk of commencing therapy by 5 years than those in the lowest quintile (HR, 3.30; 95% CI, 1.63-6,70; P < 0.001) and a 5.4 times greater risk of commencing IOP-lowering therapy by 2 years than the those in the lowest quintile (HR, 5.45; 95% CI, 2.08-14.25; P < 0.001). A higher PRS was associated with a greater risk of treatment escalation among patients receiving treatment at enrollment (HR, 1.19/SD; 95% CI, 1.09-1.31; P < 0.001). In combined analysis of all participants, participants in the top population-based quintile were at 2.3 times greater risk of requiring initiation or escalation of IOP-lowering therapy than those in the lowest quintile (HR, 2.33; 95% CI, 1.75-3.01; P < 0.001). CONCLUSIONS: This study demonstrated novel associations between glaucoma polygenic risk and risk of commencement or escalation of IOP-lowering therapy, building on previous work highlighting the potential clinical usefulness of genetic risk stratification in glaucoma. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Marshall HN, Mullany S, Han X, et al. High Polygenic Risk Is Associated with Earlier Initiation and Escalation of Treatment in Early Primary Open-Angle Glaucoma. Ophthalmology. 2023. PMID: 37044160. doi:10.1016/j.ophtha.2023.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。